Mental war among domestic companies facing Viread’s salt-modified products

While the gigantic hepatitis B therapy, ‘Viread(tenofovir disoproxil fumarate)’ is expected to be expired in its substance patent next year, competition among domestic companies have already started over follow-up products.

A part of pharmaceutical companies have also taken legal actions as registering salt-modified products for patents.

According to the industry on the 14^th, 11 companies inc...